Previous 10 | Next 10 |
2023-10-24 14:15:19 ET More on Alkermes Alkermes: A Complicated Story Right Now Lybalvi: Weighing In Light, But Tipping Alkermes' Scales Alkermes plc 2023 Q2 - Results - Earnings Call Presentation Alkermes Q3 2023 Earnings Preview Alkermes to grant Te...
2023-10-24 12:11:07 ET More on Alkermes Alkermes: A Complicated Story Right Now Lybalvi: Weighing In Light, But Tipping Alkermes' Scales Alkermes plc 2023 Q2 - Results - Earnings Call Presentation Alkermes to grant Teva license for generic Vivitrol, settles l...
NORTHAMPTON, MA / ACCESSWIRE / October 23, 2023 / Alkermes Originally published in Alkermes September 2023 Corporate Responsibility Report Alkermes' mission is to research, develop and commercialize important new medicines for patients suffering from complex medical conditions, including those...
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress PR Newswire — Initial ALKS 2680 Data Demonstrated Dose-Dependent, Significantly Improved Sleep Latency Compared to Placebo in Narcolepsy Type 1 — — ...
Alkermes to Report Third Quarter Financial Results on October 25, 2023 PR Newswire DUBLIN , Oct. 18, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday...
NORTHAMPTON, MA / ACCESSWIRE / October 16, 2023 / Alkermes This month we recognize Global Diversity Awareness Month. On Team Alkermes, we believe that diverse voices and perspectives bring immeasurable value to our organization and the patients we serve. We remain steadfast in our commitment to...
NORTHAMPTON, MA / ACCESSWIRE / October 13, 2023 / Mental Health conditions among adults are on the rise across the country, which makes mental health screening more important than ever. Check out this helpful tool from Mental Health America that may help determine if you or a loved one are exp...
NORTHAMPTON, MA / ACCESSWIRE / October 11, 2023 / Alkermes Corporate responsibility is foundational to our business. We are proud to release our latest Corporate Responsibility Report, which details our progress in 2022 related to environmental sustainability, diversity, inclusion and belonging...
Mural Oncology to Host Investor Webcast on October 17 PR Newswire — Event to be Webcast on Tuesday, October 17 at 11:00 a.m. ET — DUBLIN , Oct. 10 , 2023 /PRNewswire/ -- Mural Oncology plc , the publicly-traded oncology company t...
Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress PR Newswire — Oral Presentation to Include Initial Clinical Proof-of-Concept Data in Patients With Narcolepsy Type 1 for ALKS 2680, the Company's Investigational Orex...
News, Short Squeeze, Breakout and More Instantly...
Alkermes plc (ALKS) is expected to report $0.64 for Q2 2024 Acerinox ADR (ANIOY) is expected to report for Q2 2024 Allegion plc (ALLE) is expected to report $1.77 for Q2 2024 Deutsche Bank AG (DB) is expected to report $0.43 for Q2 2024 Pathward Financial Inc. (CASH) is expected t...
Alkermes plc Reports Second Quarter 2024 Financial Results PR Newswire — Second Quarter Revenues of $399.1 Million — — Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income from C...
2024-07-22 10:45:03 ET Enbridge Inc (ENB) ENB is trading UP for the last 5 days, and it at trading at $36.59 with volume of 731,965 and a one day change of $0.05 (0.14%). Enbridge Inc has a 52-week low of 31.03 and a 52-week high of $38.36. The business's 50-day moving average price...